On January 4, 2002, President Bush signed the Best Pharmaceuticals for Children Act (BPCA) to establish a process for studying on-patent and off-patent drugs for use in pediatric populations, and to improve pediatric therapeutics through collaboration on scientific investigation, clinical study design, weight of evidence, and ethical and labeling issues. The National Institute of Dental and Craniofacial Research (NICDR) participates in BPCA efforts on behalf of the National Institutes of Health (NIH) because of its work in children's and maternal oral health.

Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
2011
Total Cost
$176,904
Indirect Cost
Name
National Institute of Dental & Craniofacial Research
Department
Type
DUNS #
City
State
Country
Zip Code